Email News
Astrazeneca Sees 2022 Growth As Dividend Rises But COVID Boost Falls
AstraZeneca (AZN.L) on Thursday forecast higher 2022 sales and raised its annualised dividend after the drugmaker posted better-than-expected fourth-quarter profit as it gets a lift from its COVID-19 antibody treatment and cancer drugs.
Recipient Email:
*
Your name:
*
Your Email:
*